Wall Street is positive on Tonix Pharmaceuticals Holding Corp (TNXP). On average, analysts give the stock a Buy rating. The average price target is $6.5, which means analysts expect the stock to climb by 815.49% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 39, which is better than 39% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Tonix Pharmaceuticals Holding Corp Stock Today?
Tonix Pharmaceuticals Holding Corp (TNXP) stock is down -4.2% while the S&P 500 is higher by 4.23% as of 1:51 PM on Thursday, Mar 26. TNXP has fallen -$0.03 from the previous closing price of $0.74 on volume of 3,371,404 shares. Over the past year the S&P 500 is lower by -8.02% while TNXP has fallen -97.20%. TNXP lost -$19.33 per share the over the last 12 months.
